All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Interferon Beta-1A
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: SNG001
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Aerogen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 23, 2020
Details:
Synairgen’s SNG001 among the many potential treatments and vaccines to be delivered via Aerogen’s aerosol drug delivery system .
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Interferon Beta-1A
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: SNG001
Highest Development Status: Phase II Product Type: Large molecule
Recipient: Parexel Biotech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 20, 2020
Details:
Synairgen’s study will evaluate the ability of SNG001, an inhaled formulation of IFN-beta-1a, to accelerate recovery among hospitalized patients receiving oxygen.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Interferon Beta-1A
Therapeutic Area: Infections and Infectious Diseases Product Name: SNG001
Highest Development Status: Phase II Product Type: Large molecule
Recipient: Akron Biotech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 19, 2020
Details:
Akron will support the future clinical and commercial development of SNG001 through the provision of its IFN-beta in Synairgen’s formulation.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Interferon Beta-1A
Therapeutic Area: Infections and Infectious Diseases Product Name: SNG001
Highest Development Status: Phase II Product Type: Large molecule
Recipient: Clinigen Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 29, 2020
Details:
The collaboration will be working to progress SNG001 through the required clinical and regulatory channels to make this potentially critical treatment widely available to COVID-19 patients around the world.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Interferon Beta-1A
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: SNG001
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2020
Details:
SNG001 was well tolerated during the treatment period in a study population that was elderly (mean age 66 years) and suffering from reduced respiratory function, as measured by forced expiratory volume in one second.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Interferon Beta-1A
Therapeutic Area: Infections and Infectious Diseases Product Name: SNG001
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2020
Details:
The trial of SNG001 in hospitalised COVID-19 patients is a Phase II trial (as clearly stated in the announcements of 18 and 25 March). A Phase II trial is designed to test the efficacy of a drug and takes place before the drug is approved or able to be marketed.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Interferon Beta-1A
Therapeutic Area: Infections and Infectious Diseases Product Name: SNG001
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2020
Details:
The data showed those who were given SNG001 had a 79% lower risk of developing severe disease compared to placebo, according to the biotech, with patients who got that drug also more than twice as likely to recover from COVID-19 than those on a dummy med.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Interferon Beta-1A
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2020
Details:
The new trial is an expansion of the original hospital-based SG016 study. SNG001 is an inhaled formulation of interferon-beta-1a, a natural protein associated with the body’s antiviral responses.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Interferon Beta-1A
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 18, 2020
Details:
Company has received expedited approvals from the MHRA and Health Research Authority to conduct a trial of SNG001 in COVID-19 patients to potentially assist with the global outbreak of the virus.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
